Setting itself apart from the other players that only focus on the deciphering of DNA sequences for research purposes,
GC Genome is moving toward the goal of utilizing genomic information for disease diagnosis, disease screening and also precision medicine.
GC Genome leverages on the most up to date technologies including Next-Generation Sequencing (NGS) to provide distinguished services with shortened turnaround time, and affordable prices.
Moreover, we continue to invest heavily on R&D activities to develop services to fulfill the unmet needs of people and participate in the advancement of various global and national research projects.
Keep an eye out for GC Genome as we develop into a frontier company in genomic diagnostics and we will answer your support with our endless efforts and challenges.
Thank you.
Mission
Contribute to the Healthy Lives of People
Vision
The Frontier Company in Genomic Diagnostics
History
2019
Launched GreenBiome Gut (Microbiome Test) 10
Launched Distribution of Guardant 360 in Korea 07
2017
Selected as the Supervisory Institution for the Korea-Czech Republic 11
Global R&D Cooperation project Selected for Bio-industry Core R&D Project 10 Obtained KFDA Certification of Clinical NGS Laboratory 04 Obtained CAP accreditation 02
Launched Pharmacogenetic Test 11 Selected as a supervisory institution for Korea Post-Genome Project 08 Obtained Level A (best accuracy) from the Korea Institute of 07
Genetic Testing Evaluation Launched G-NIPT (Non-invasive prenatal Test) 04
2015
07 Overall reorganization of web site 05 Launched ‘Cancer Risk Screen plus Alcohol’ (Screening Test) 04 Launched ‘Eye(or Ocular) Disease Risk Screen’ (Screening Test)
03 Launched ‘Greenbiome Perio & Denti’ (Microbiome Test) 02 Introduced WGS(Whole Genome Sequencing) for diagnosis domestically
2020
2018
10 Obtained CAP accreditation (2nd time) 04 Launched NGS-based preventive screening test Genome Screen
(1st in Korea)
04 Launched series of clinical genetic test items - Diagnostic Exome Sequencing Service (1st in Korea) for rare disease patients - Type 1 Myotonic Dystrophy carrier screening - Hereditary Cancer Test
2013
Genome Research Center approved by the Korean Government 12 GC Genome Established08
